1. Concomitant Mitral Regurgitation in Severe Aortic Stenosis - A Report From the CURRENT AS Registry.
- Author
-
Murai R, Kawase Y, Taniguchi T, Morimoto T, Kadota K, Ohya M, Shimada T, Maruo T, Fuku Y, Komiya T, Ando K, Hanyu M, Kanamori N, Aoyama T, Murata K, Onodera T, Yamazaki F, Kitai T, Furukawa Y, Koyama T, Miyake M, Izumi C, Nakagawa Y, Yamanaka K, Mitsuoka H, Shirotani M, Kato M, Miki S, Nakajima H, Hirano Y, Miyazaki S, Saga T, Sugioka S, Matsuda S, Matsuda M, Ogawa T, Nagao K, Inada T, Nakayama S, Mabuchi H, Takeuchi Y, Sakamoto H, Sakaguchi G, Yamane K, Eizawa H, Toyofuku M, Tamura T, Iwakura A, Ishii M, Akao M, Shiraga K, Minamino-Muta E, Kato T, Inoko M, Ueyama K, Ikeda T, Himura Y, Komasa A, Ishii K, Hotta K, Sato Y, Fujiwara K, Kato Y, Kouchi I, Inuzuka Y, Ikeguchi S, Miwa S, Maeda C, Shinoda E, Nishizawa J, Jinnai T, Higashitani N, Kitano M, Morikami Y, Kitaguchi S, Minatoya K, and Kimura T
- Subjects
- Aortic Valve surgery, Humans, Registries, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Aortic Valve Stenosis complications, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Heart Valve Prosthesis Implantation adverse effects, Mitral Valve Insufficiency complications, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency epidemiology
- Abstract
Background: The clinical significance of concomitant mitral regurgitation (MR) has not been well addressed in patients with severe aortic stenosis (AS)., Methods and results: We analyzed 3,815 patients from a retrospective multicenter registry of severe AS in Japan (CURRENT AS registry). We compared the clinical outcomes between patients with moderate/severe MR and with none/mild MR according to the initial treatment strategy (initial aortic valve replacement [AVR] or conservative strategy). The primary outcome measure was a composite of aortic valve-related death or heart failure hospitalization. At baseline, moderate/severe MR was present in 227/1,197 (19%) patients with initial AVR strategy and in 536/2,618 (20%) patients with a conservative strategy. The crude cumulative 5-year incidence of the primary outcome measure was significantly higher in patients with moderate/severe MR than in those with none/mild MR, regardless of the initial treatment strategy (25.2% vs. 14.4%, P<0.001 in the initial AVR strategy, and 63.3% vs. 40.7%, P<0.001 in the conservative strategy). After adjusting confounders, moderate/severe MR was not independently associated with higher risk for the primary outcome measure in the initial AVR strategy (hazard ratio [HR] 1.11, 95% confidence interval [CI] 0.67-1.83, P=0.69), and in the conservative strategy (HR 1.13, 95% CI 0.93-1.37, P=0.22)., Conclusions: Concomitant moderate/severe MR was not independently associated with higher risk for the primary outcome measure regardless of the initial treatment strategy.
- Published
- 2022
- Full Text
- View/download PDF